Rallybio Corp

Rallybio (Nasdaq: RLYB) is a clinical-stage biotechnology company developing therapies for severe and rare diseases. Its lead candidate, RLYB116, is a C5 inhibitor being studied for complement-mediated disorders, including immune platelet transfusion refractoriness and antiphospholipid syndrome; the engineered protein is designed for once-weekly subcutaneous administration. Rallybio has completed two Phase 1 studies in healthy participants. Its RLYB332 program, a long-acting antibody targeting matriptase-2, is in preclinical development for diseases involving iron overload and ineffective red blood cell production, including beta thalassemia and some myelodysplastic syndromes. The company also has collaborations focused on antibody discovery for rare diseases and is eligible for milestone and royalty payments related to the sale of its preclinical ENPP1 inhibitor program to Recursion. In March 2026, Rallybio agreed to merge with Candid Therapeutics, which is developing T-cell engager therapies for autoimmune diseases; the proposed transaction includes a concurrent financing. Rallybio’s pipeline programs are subject to a contingent value rights arrangement in connection with the merger. Its website is www.rallybio.com.